Elan chief explains J&J's Tysabri option

Tysabri rumors have smoked out Elan CEO Kelly Martin (photo). The flurry of talk about Johnson & Johnson's "arrangement" with Elan on the MS drug prompted Martin to come out with details. And here they are: J&J has an option to help finance Elan's purchase of Biogen Idec's rights to Tysabri in the event that Biogen is acquired. Under that scenario, J&J would end up as Elan's 50-50 partner on the drug.

Martin's remarks come after word started leaking out, with sources speculating in the media that J&J might have outright acquired Elan's right to buy Biogen's Tysabri share. As you know, Elan and Biogen's Tysabri partnership includes a provision granting each company the right to buy Tysabri if the other is acquired. J&J is now Elan's largest shareholder, having bought an 18 percent-plus share of the firm for $1 billion.

Elan granted J&J the option to finance a Tysabri buy because the Irish company couldn't afford to do so by itself, Martin told Bloomberg. "We wanted to make sure we were not flat-footed from a financing point of view," Martin told the news service. "Why on Earth would we ever want to sell our half of the asset?"

- read the Bloomberg story
- get more from the WSJ Health Blog

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.